CUE BIOPHARMA INC. -

Cue Biopharma Granted U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101

21 Sep 2021 07:00:02 By Nasdaq GlobeNewswire

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences

09 Sep 2021 07:00:02 By Nasdaq GlobeNewswire

Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and Business Highlights

17 Aug 2021 15:01:00 By Nasdaq GlobeNewswire

Cue Biopharma to Host Business Update Call and Webcast

10 Aug 2021 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma to Present Corporate Update at the Upcoming BTIG Virtual Biotechnology Conference

03 Aug 2021 07:01:12 By Nasdaq GlobeNewswire

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

14 Jun 2021 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC

10 Jun 2021 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting

03 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Cue Biopharma to Present a Corporate and Clinical Progress Update at the Upcoming Jefferies Virtual Healthcare Conference

26 May 2021 07:00:02 By Nasdaq GlobeNewswire

Cue Biopharma Reports First Quarter 2021 Results, Recent Updates of CUE-101 Phase 1 Dose Escalation Study, Platform Progress and Business Highlights

17 May 2021 15:01:00 By Nasdaq GlobeNewswire

Cue Biopharma to Host Business Update Call and Webcast

10 May 2021 09:00:00 By Nasdaq GlobeNewswire

Cue Biopharma Reports Confirmed Partial Response (PR) in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer

10 May 2021 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma to Present at the 2021 Frontiers in Cancer Immunotherapy Conference

06 May 2021 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

16 Mar 2021 15:01:00 By Nasdaq GlobeNewswire

Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference

15 Mar 2021 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma to Host Business Update Call and Webcast

09 Mar 2021 07:00:00 By Nasdaq GlobeNewswire

Cue Biopharma to Present at the Cowen 41st Annual Health Care Conference

01 Mar 2021 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma Enhances Scientific Advisory Board with Appointments of Immunology and Immunotherapy Experts Dr. Abul K. Abbas and Dr. Michael Kalos

25 Feb 2021 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development

17 Feb 2021 07:00:01 By Nasdaq GlobeNewswire

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer

08 Feb 2021 07:00:01 By Nasdaq GlobeNewswire